Oziltus (denosumab-mobz, biosimilar to Prolia/Xgeva)
Named-patient access overview. Oziltus is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Oziltus
Oziltus (denosumab-mobz) is a biosimilar to denosumab, the reference monoclonal antibody marketed by Amgen as Prolia and Xgeva. Denosumab is a fully human IgG2 monoclonal antibody that binds and inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), the cytokine that drives osteoclast formation, function, and survival. Blocking RANKL reduces bone resorption and slows the bone-destruction processes that underlie both osteoporosis and certain cancer-related bone disease.
Oziltus is administered by subcutaneous injection on a fixed dosing schedule that depends on the indication. Reference-product indications include postmenopausal osteoporosis at high risk of fracture, bone loss in patients on certain cancer therapies, prevention of skeletal-related events in adults with bone metastases from solid tumors, and giant cell tumor of bone. Biosimilar-specific labelling and indication coverage should be confirmed against the current FDA label for denosumab-mobz before prescribing.
For international patients, Oziltus is sourced by Reserve Meds from a DSCSA-compliant US specialty wholesaler with full serial traceability and may be accessible via Named Patient Program or personal-import pathways depending on destination country.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Oziltus
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Oziltus for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Oziltus is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Oziltus in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Oziltus
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.